{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69","upperLimit":"99","value":"84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"of a 3-phase comprehensive treatment approach including induction with BD followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with newly diagnosed AL amyloidosis","id":"OG000","title":"Amyloidosis"}],"paramType":"NUMBER","populationDescription":"Data were not collected for MIDD group.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Percentage of Participants Experiencing Progression Free Survival at 12 Months","type":"PRIMARY","unitOfMeasure":"percentage of patients"}